We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Share News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amryt Pharma Completes Combination With Aegerion Pharmaceuticals

Wed, 25th Sep 2019 12:24

(Alliance News) - Amryt Pharma PLC has completed the takeover of Aegerion Pharmaceuticals Inc, it said on Wednesday, and shares have now been readmitted to trading in London.

Amryt shares had been suspended as the deal represented a reverse takeover under AIM rules. The deal for Aegerion, a subsidiary of Novelion Therapeutics Inc, was first announced in May.

Amryt shares were trading at 131.15 pence each following readmission, down 1.4%.

Amryt has paid for the business via USD85 million of contingent value rights based on some milestones being achieved. Aegerion was restructured in a US bankruptcy court prior to the deal.

Alongside the transaction, Amryt said in May it would be raising USD60 million via a share placing, which has now been completed. It issued shares at USD1.79 each, and has also signed a USD81.9 million secured facility and issued USD125 million of convertible notes to Aegerion creditors.

Amryt Chief Executive Joe Wiley commented: "Amryt has come a long way since the company was set up in August 2015. On completion of the acquisition today, Amryt has two substantial revenue-generating products with built-in 2018 revenue of USD136.5 million, a ready-made international commercial business in the US, Europe, the Middle East and Latin America, a strong development pipeline and the financial flexibility to fully execute on our growth plans.

"Integration of the two businesses is already well underway and we are confident in the opportunities the deal will deliver for all of our stakeholders, and the transaction will drive future shareholder value. We are particularly excited about growth opportunities in Europe following the recent approval of Myalepta by the EMA in July 2018."

The acquisition, which was endorsed by 34% of Amryt shareholders and more than 67% of Aegerion's bondholders, creates a rare disease business with two approved products, Lojuxta and Myalept.

These drugs treat genetic disorders familial hypercholesterolemia and generalised lipodystrophy, respectively.

By George Collard; georgecollard@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
9 Dec 2020 09:47

Amryt Pharma gets approval for 'Lojuxta' in Brazil

(Sharecast News) - Biopharmaceutical company Amryt Pharma announced on Wednesday that it has received marketing authorisation approval from the Brazilian Health Regulatory Agency (ANVISA) for 'Lojuxta', or lomitapide.

Read more
8 Dec 2020 09:22

Amryt Pharma raising $40m for working capital, acquisitions

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has entered into agreements to raise $40m, it announced on Tuesday, to fund working capital as well as potential acquisitions and licence deals.

Read more
29 Oct 2020 19:11

IN BRIEF: Amryt Pharma Posts Success From Filsuvez Trial

IN BRIEF: Amryt Pharma Posts Success From Filsuvez Trial

Read more
29 Oct 2020 16:09

Amryt shares rise on success of 'EASE' trial

(Sharecast News) - Biopharmaceutical company Amryt Pharma announced positive results from its pivotal phase 23 'EASE' trial of 'Filsuvez', or 'Oleogel-S10', previously 'AP101', on Thursday.

Read more
29 Oct 2020 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
19 Oct 2020 15:43

IN BRIEF: Amryt Pharma Signs Distribution Deal With Swixx Biopharma

IN BRIEF: Amryt Pharma Signs Distribution Deal With Swixx Biopharma

Read more
19 Oct 2020 08:34

Amryt Pharma signs new distribution deal with Swixx BioPharma

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the signing of a distribution agreement with Swixx BioPharma of Baar, Switzerland on Monday.

Read more
15 Sep 2020 22:08

UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life

UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life

Read more
9 Sep 2020 13:26

Amryt shares surge on Filsuvez phase 3 results

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced positive top-line results from its pivotal phase 3 'EASE' trial of 'Filsuvez' for the treatment of dystrophic and junctional epidermolysis bullosa on Wednesday.

Read more
9 Sep 2020 10:50

UK WINNERS & LOSERS SUMMARY: Amryt Surges Nearly 50% On Trial Results

UK WINNERS & LOSERS SUMMARY: Amryt Surges Nearly 50% On Trial Results

Read more
9 Sep 2020 10:31

Amryt Pharma Shares Jump On Positive Third-Phase Filsuvez Trial Result

Amryt Pharma Shares Jump On Positive Third-Phase Filsuvez Trial Result

Read more
8 Jul 2020 17:13

IN BRIEF: Amryt Lauds Nasdaq Global Listing "Milestone"

IN BRIEF: Amryt Lauds Nasdaq Global Listing "Milestone"

Read more
24 Jun 2020 14:12

IN BRIEF: Amryt Pharma To List American Depository Shares In US

IN BRIEF: Amryt Pharma To List American Depository Shares In US

Read more
4 Jun 2020 14:58

UK DIRECTOR DEALINGS SUMMARY: XP Power Chair In GBP3.6 Million Sale

UK DIRECTOR DEALINGS SUMMARY: XP Power Chair In GBP3.6 Million Sale

Read more
3 Jun 2020 16:23

UK DIRECTOR DEALINGS SUMMARY: Braveheart Investment CEO Cuts Stake

UK DIRECTOR DEALINGS SUMMARY: Braveheart Investment CEO Cuts Stake

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.